Abstract

Bone metastasis is an incurable complication of breast cancer. In advanced stages, patients with estrogen-positive tumors experience a significantly higher incidence of bone metastasis (>87%) compared to estrogen-negative patients (<56%). To understand the mechanism of this bone-tropism of ER+ tumor, and to identify liquid biopsy biomarkers for patients with high risk of bone metastasis, the secreted extracellular vesicles and cytokines from bone-tropic breast cancer cells are examined in this study. Both exosomal miR-19a and Integrin-Binding Sialoprotein (IBSP) are found to be significantly upregulated and secreted from bone-tropic ER+ breast cancer cells, increasing their levels in the circulation of patients. IBSP is found to attract osteoclast cells and create an osteoclast-enriched environment in the bone, assisting the delivery of exosomal miR-19a to osteoclast to induce osteoclastogenesis. Our findings reveal a mechanism by which ER+ breast cancer cells create a microenvironment favorable for colonization in the bone. These two secreted factors can also serve as effective biomarkers for ER+ breast cancer to predict their risks of bone metastasis. Furthermore, our screening of a natural compound library identifies chlorogenic acid as a potent inhibitor for IBSP-receptor binding to suppress bone metastasis of ER+ tumor, suggesting its preventive use for bone recurrence in ER+ patients.

Bone metastasis is a major complication of breast cancer (BC) and ER+ tumors have a higher incidence of bone metastasis than ER tumors. Here, the authors report that miR‐19a in exosomes and the bone matrix protein, IBSP, are upregulated and secreted by bone tropic ER+ BC cells, where they cooperatively induce osteoclastogenesis and promote bone colonization.

Details

Title
Exosomal miR-19a and IBSP cooperate to induce osteolytic bone metastasis of estrogen receptor-positive breast cancer
Author
Wu Kerui 1 ; Feng Jiamei 2 ; Lyu Feng 3 ; Xing Fei 1   VIAFID ORCID Logo  ; Sharma Sambad 1 ; Liu, Yin 1 ; Shih-Ying, Wu 1 ; Zhao, Dan 1   VIAFID ORCID Logo  ; Tyagi Abhishek 1   VIAFID ORCID Logo  ; Deshpande, Ravindra Pramod 1 ; Xinhong, Pei 4 ; Ruiz Marco Gabril 1 ; Takahashi, Hiroyuki 5 ; Tsuzuki Shunsuke 5 ; Kimura Takahiro 5 ; Yin-yuan, Mo 6 ; Shiozawa Yusuke 1   VIAFID ORCID Logo  ; Singh, Ravi 1   VIAFID ORCID Logo  ; Watabe Kounosuke 1   VIAFID ORCID Logo 

 Wake Forest University School of Medicine, Department of Cancer Biology, Winston-Salem, USA (GRID:grid.241167.7) (ISNI:0000 0001 2185 3318) 
 Wake Forest University School of Medicine, Department of Cancer Biology, Winston-Salem, USA (GRID:grid.241167.7) (ISNI:0000 0001 2185 3318); Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Mammary Department, Shanghai, China (GRID:grid.412585.f) (ISNI:0000 0004 0604 8558) 
 Wake Forest University School of Medicine, Department of Cancer Biology, Winston-Salem, USA (GRID:grid.241167.7) (ISNI:0000 0001 2185 3318); Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, People’s Hospital of Henan University, Department of Breast Surgery, Zhengzhou, China (GRID:grid.414011.1) (ISNI:0000 0004 1808 090X) 
 Wake Forest University School of Medicine, Department of Cancer Biology, Winston-Salem, USA (GRID:grid.241167.7) (ISNI:0000 0001 2185 3318); The First Affiliated Hospital of Zhengzhou University, Department of Breast Surgery, Zhengzhou, China (GRID:grid.412633.1) 
 Jikei University School of Medicine, Department of Pathology, Minato City, Japan (GRID:grid.411898.d) (ISNI:0000 0001 0661 2073) 
 University of Mississippi Medical Center, Cancer Institute, Jackson, USA (GRID:grid.410721.1) (ISNI:0000 0004 1937 0407) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2567802030
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.